WallStreetZenWallStreetZen

NASDAQ: ALLO
Allogene Therapeutics Inc Stock Ownership - Who owns Allogene Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Allogene Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
David D. ChangPresident and CEO2024-03-1453,393$4.33
$231.19kSell
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER2024-01-30190$3.60
$683.05Buy
Zachary RobertsEVP of RD2024-01-2224,690$3.17
$78.37kSell
Deborah M. MessemerDirector2023-12-1818,640$2.70
$50.31kSell
Stephen MayoDirector2023-08-0710,000$4.29
$42.85kSell

1 of 1

ALLO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALLO insiders and whales buy or sell their stock.

ALLO Shareholders

What type of owners hold Allogene Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Fmr LLC14.93%25,241,499$85.82MInstitution
Pfizer Inc13.03%22,032,040$74.91MInsider
Tpg GP A LLC11.07%18,716,306$63.64MInsider
Tpg Group Holdings Sbs Advisors Inc11.07%18,716,306$63.64MInsider
Tpg GP A LLC11.07%18,716,306$63.64MInstitution
Blackrock Inc5.92%10,001,804$34.01MInstitution
Vanguard Group Inc5.34%9,030,825$30.70MInstitution
Jpmorgan Chase Co4.08%6,906,761$23.48MInstitution
Arie Belldegrun3.89%6,576,979$22.36MInsider
David D. Chang3.15%5,321,322$18.09MInsider

1 of 3

ALLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALLO60.41%39.59%Net SellingNet Selling
MLYS56.06%43.94%Net BuyingNet Buying
VERV62.25%37.75%Net BuyingNet Selling
PRME32.55%67.45%Net BuyingNet Buying
PROK12.81%8.98%Net SellingNet Selling
View Top Biotech Stocks

Allogene Therapeutics Stock Ownership FAQ

Who owns Allogene Therapeutics?

Allogene Therapeutics (NASDAQ: ALLO) is owned by 71.85% institutional shareholders, 47.08% Allogene Therapeutics insiders, and 0.00% retail investors. Pfizer Inc is the largest individual Allogene Therapeutics shareholder, owning 22.03M shares representing 13.03% of the company. Pfizer Inc's Allogene Therapeutics shares are currently valued at $74.25M.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.